Tae Won Kim

1991–2026 年に発表

別表記
Tae‐Won Kim · Tae-Won Kim · Tae-won Kim
192
論文数
23,189
被引用数
75
h 指数
162
i10 指数

被引用数

Tae Won Kim の年別被引用数1979 年: 被引用 1 件1991 年: 被引用 2 件1992 年: 被引用 1 件1993 年: 被引用 1 件1994 年: 被引用 2 件1996 年: 被引用 3 件1998 年: 被引用 2 件1999 年: 被引用 3 件2001 年: 被引用 2 件2002 年: 被引用 6 件2003 年: 被引用 2 件2004 年: 被引用 14 件2005 年: 被引用 12 件2006 年: 被引用 17 件2007 年: 被引用 18 件2008 年: 被引用 32 件2009 年: 被引用 29 件2010 年: 被引用 40 件2011 年: 被引用 39 件2012 年: 被引用 50 件2013 年: 被引用 47 件2014 年: 被引用 51 件2015 年: 被引用 80 件2016 年: 被引用 96 件2017 年: 被引用 111 件2018 年: 被引用 122 件2019 年: 被引用 424 件2020 年: 被引用 754 件2021 年: 被引用 1,261 件2022 年: 被引用 1,157 件2023 年: 被引用 1,032 件2024 年: 被引用 1,714 件2025 年: 被引用 946 件2026 年: 被引用 42 件1980〜1990 年は被引用が無いため表示していません1995 年は被引用が無いため表示していません1997 年は被引用が無いため表示していません2000 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 2,196 件、この内訳の 21.5%中国: 引用元論文 1,484 件、この内訳の 14.5%イタリア: 引用元論文 640 件、この内訳の 6.3%イギリス: 引用元論文 533 件、この内訳の 5.2%ドイツ: 引用元論文 467 件、この内訳の 4.6%フランス: 引用元論文 466 件、この内訳の 4.5%日本: 引用元論文 412 件、この内訳の 4%韓国: 引用元論文 373 件、この内訳の 3.6%スペイン: 引用元論文 367 件、この内訳の 3.6%オランダ: 引用元論文 298 件、この内訳の 2.9%カナダ: 引用元論文 248 件、この内訳の 2.4%オーストラリア: 引用元論文 241 件、この内訳の 2.4%
0%21.5%その他 24.5%

分野

  • Medicine62.7%
  • Biochemistry, Genetics and Molecular Biology20.9%
  • Neuroscience3.5%
  • Immunology and Microbiology3.1%
  • Computer Science2.3%
  • Engineering2%
  • その他5.5%

トピック

  • Colorectal Cancer Treatments and Studies7.9%
  • Cancer Immunotherapy and Biomarkers7.3%
  • Genetic factors in colorectal cancer4.2%
  • Cancer Genomics and Diagnostics3.6%
  • Lung Cancer Treatments and Mutations2.6%
  • Colorectal Cancer Surgical Treatments2.5%
  • その他71.9%

共著者

全論文

検索で開く
  1. Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer

    著者: , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2020 被引用: 2,954

  2. KRAS G12C Inhibition with Sotorasib in Advanced Solid Tumors

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Gregory Friberg, Piro Lito, Ramaswamy Govindan, Bob T. Li - New England Journal of Medicine 2020 被引用: 1,687

  3. Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study

    著者: , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2022 被引用: 894

  4. Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Michael D. Pickard, Janna Christy‐Bittel, Lisa Anderson, Victor Sandor, Josep Tabernero - New England Journal of Medicine 2019 被引用: 1,465

  5. Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2023 被引用: 294

  6. Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C

    著者: , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2023 被引用: 342

  7. Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability–High/Mismatch Repair–Deficient Metastatic Colorectal Cancer: KEYNOTE-164

    著者: , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2019 被引用: 1,014

  8. Neural network analysis of sleep stages enables efficient diagnosis of narcolepsy

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Nature Communications 2018 被引用: 398

  9. Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial

    著者: , , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2021 被引用: 288

  10. Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Derek K. Chu, Félix Couture, Jennifer L. Cultrera, David Cunningham, Eric Van Cutsem, P-J. Cuyle, Janine M. Davies, Scot Dowden, Mikhail Dvorkin, Vinod Ganju, RV Garcia, Rachel Kerr, Tae‐Yop Kim, Kevin G. King, Jeremy Kortmansky, Mark Kozloff, Ko Lam, J Lee, AS Lee, Bernard Lespérance, Gabriele Luppi, Boyu Ma, Evaristo Maiello, Romeo A. Mandanas, J. L. Marshall, Gavin Marx, Saifee Mullamitha, Marina Nechaeva, Jo Park, Nick Pavlakis, CG Ponce, Piotr Potemski, Sherif Raouf, James A. Reeves, Neil H. Segal, Salvatore Siena, Alexey Smolin, JO Streb, A. H. Strickland, Ewa Szutowicz-Zielińska, Josep Tabernero, Benjamin Tan, JS Valera, Marc Van den Eynde, Philippe Vergauwe, Michael M. Vickers, Mark Womack, Marta Wróblewska, Ruth T. Young - The Lancet Oncology 2019 被引用: 562

  11. Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Zhen Shi, Sandhya Mandlekar, Mark T. Lin, Stephanie Royer‐Joo, Julie Chang, Tomi Jun, Neekesh V. Dharia, Jennifer L. Schutzman, GO42144 Investigator and Study Group, Sae-Won Han - Nature Medicine 2023 被引用: 122

  12. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study

    著者: , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2015 被引用: 955

  13. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial

    著者: , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2015 被引用: 816

  14. The Impact of Sleep and Circadian Disturbance on Hormones and Metabolism

    著者: , , - International Journal of Endocrinology 2015 被引用: 349

  15. Anti-TIGIT Antibody Tiragolumab Alone or With Atezolizumab in Patients With Advanced Solid Tumors

    著者: , , , , , , , , , , , , , , , , , , , , , , , - JAMA Oncology 2023 被引用: 63

  16. ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Yoon-Hee Hong, Young Su Noh, Munjeong Choi, Oakpil Han, Małgorzata Nowicka, Shrividhya Srinivasan, Yibing Yan, Tae Won Kim, Shiva Malek - Nature 2021 被引用: 135

  17. Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial

    著者: , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2021 被引用: 220

  18. Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study

    著者: , , , , , , , , , , , - The Lancet Oncology 2014 被引用: 470

  19. Lenvatinib Plus Pembrolizumab Versus Standard of Care for Previously Treated Metastatic Colorectal Cancer: Final Analysis of the Randomized, Open-Label, Phase III LEAP-017 Study

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Matthew Burge, Sumitra Ananda, Muhammad A. Khattak, Bruce Colwell, Félix Couture, Brandon M. Meyers, Kathryn Towns, Michael B. Sawyer, Lucas Sidéris, Rui‐Hua Xu, Wei Wang, Hongming Pan, Per Pfeiffer, Lars Henrik Jensen, Camilla Qvortrup, Sebastian Stintzing, Dirk Arnold, Sylvie Lorenzen, Stefan Kubicka, Reinhard Depenbusch, Maria Passhak, Ravit Geva, Ayala Hubert, Einat Shacham‐Shmueli, Gleb Kornev, Akihito Kawazoe, Toshiki Masuishi, Atsuo Takashima, Hiroki Hara, Hisato Kawakami, Nozomu Machida, Kentaro Yamazaki, Hisateru Yasui, Akihito Tsuji, Taito Esaki, Kensei Yamaguchi, Tae‐You Kim, Joong Bae Ahn, Myung Ah Lee, Tae Won Kim, Joon Oh Park, Soo Hyun Lee, Р. В. Орлова, V. O. Sarzhevskiy, Marina Sekacheva, S. Tjulandin, Oksana Shirokova, A.I. Iskhakova Iskhakova, A. A. Lebedinets, Paula Jiménez Fonseca, F. Rivera Herrero, Elena Elez Fernandez, Pilar Alfonso, M.J. Gómez Reina, Kun‐Huei Yeh, Hao‐Wei Teng, Tsai Sheng Yang, Hwei‐Ming Wang, Yu‐Min Yeh, Mustafa Özgüroğlu, Mahmut Gumus, Şuayib Yalçın, Bülent Erdoğan, Umut Demırcı, Pınar Gürsoy, Hakan Harputluoğlu, Atakan Demir, Kai‐Keen Shiu, Ewan Brown, Paul J. Ross ほか 13 名 - Journal of Clinical Oncology 2024 被引用: 77

  20. Pembrolizumab for previously treated, microsatellite instability–high/mismatch repair–deficient advanced colorectal cancer: final analysis of KEYNOTE-164

    著者: , , , , , , , , , , , , , , , , , , , - European Journal of Cancer 2023 被引用: 93

  21. Results of a Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Trifluridine/Tipiracil (TAS-102) Monotherapy in Asian Patients With Previously Treated Metastatic Colorectal Cancer: The TERRA Study

    著者: , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2017 被引用: 257

  22. Regorafenib plus nivolumab in unresectable hepatocellular carcinoma: the phase 2 RENOBATE trial

    著者: , , , , , , , , , , , , , , , , , , - Nature Medicine 2024 被引用: 67

  23. Tumor-intrinsic expression of the autophagy gene Atg16l1 suppresses anti-tumor immunity in colorectal cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , - Nature Communications 2023 被引用: 38

  24. Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial

    著者: , , , , , , , , , , , , , , - Nature Medicine 2025 被引用: 101